Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention

Journal of General Internal Medicine

Volumn 32, Issue 6, 2017, Pages 660-666

  D’Onofrio, Gail ^a   Chawarski, Marek C ^a   O’Connor, Patrick G ^a   Pantalon, Michael V ^a   Busch, Susan H ^b   Owens, Patricia H ^a   Hawk, Kathryn ^a   Bernstein, Steven L ^a   Fiellin, David A ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

emergency medicine; opioid use disorder; primary care; substance use disorder

Indexed keywords

BUPRENORPHINE; OPIATE; NARCOTIC ANTAGONIST;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG USE; EMERGENCY WARD; EVALUATION STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PATIENT REFERRAL; PATIENT-REPORTED OUTCOME; PRIMARY MEDICAL CARE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; HOSPITAL EMERGENCY SERVICE; OPIATE SUBSTITUTION TREATMENT; OUTCOME ASSESSMENT; PRIMARY HEALTH CARE; PROCEDURES; SELF REPORT; URINE; YOUNG ADULT;

ADULT; BUPRENORPHINE; EMERGENCY SERVICE, HOSPITAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; OUTCOME ASSESSMENT (HEALTH CARE); PRIMARY HEALTH CARE; REFERRAL AND CONSULTATION; SELF REPORT; YOUNG ADULT;

EID: 85012261817     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-017-3993-2     Document Type: Article

References (26)

1. Centers for Disease Control, Prevention. Emergency department visits involving nonmedical use of selected prescription drugs - United States, 2004–2008. MMWR Morb Mortal Wkly Rep. 2010;59(23):705–9.
2. Centers for Disease Control, Prevention. CDC grand rounds: prescription drug overdoses - a U.S. epidemic. MMWR Morb Mortal Wkly Rep. 2012;61(1):10–3.
3. Surgeon General Report: U.S. Department of Health and Human Services (HHS), Office of the Surgeon General, Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health, Executive Summary. Washington, DC: HHS, November 2016.
4. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011;8:CD004145.
5. Anonymous. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: World Health Organization; 2009.
6. D’Onofrio G, O’Connor PG, Pantalon MV, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636–44.
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR: Text Revision: American Psychiatric Press Incorporated (DC); 2000.
8. Schulz KF, Grimes DA. Generation of allocation sequences in randomised trials: chance, not choice. Lancet. 2002;359(9305):515–9.
9. D’Onofrio G, Pantalon MV, Degutis LC, et al. Brief intervention for hazardous and harmful drinkers in the emergency department. Ann Emerg Med. 2008;51(6):742–50.
10. D’Onofrio G, Pantalon MV, Degutis LC, et al. Development and implementation of an emergency practitioner-performed brief intervention for hazardous and harmful drinkers in the emergency department. Acad Emerg Med. 2005;12(3):249–56.
11. Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs. 2003;35(2):253–9.
12. Lee JD, Grossman E, DiRocco D, Gourevitch MN. Home buprenorphine/naloxone induction in primary care. J Gen Intern Med. 2009;24(2):226–32.
13. Fiellin DA, Barry DT, Sullivan LE, et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med. 2013;126(1):74–e11.
14. Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355(4):365–74.
15. McLellan TA, Zanis D, Incmikoski R. Treatment Service Review (TSR). Philadelphia: The Center for Studies in Addiction, Department of Psychiatry: Philadelphia VA Medical Center & The University of Pennsylvania; 1989.
16. McLellan AT, Alterman AI, Cacciola J, Metzger D. A new measure of substance abuse treatment. Initial studies of the treatment services review. J Nerv Ment Dis. 1992;180(2):101–10.
17. Sobell L, Sobell M. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten R, Allen J, eds. Measuring Alcohol Consumption: Psychosocial and Biological Methods. Totowa, NJ: Humana Press; 1992:41–72.
18. Darke S, Hall W, Heather N, Ward J, Wodak A. The reliability and validity of a scale to measure HIV risk taking behaviour among intravenous drug users. Aids. 1991;5(2):181–186.
19. IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.
20. Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O’Connor PG. Primary care–based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(12):1947–54.
21. O’Connor P, Oliveto A, Shi J, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med. 1998;105(2):100–5.
22. Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005;20(11):1038–41.
23. Suzuki J, Matthews ML, Brick D, et al. Implementation of a collaborative care management program with buprenorphine in primary care: a comparison between opioid-dependent patients and chronic pain patients using opioids non-medically. J Opioid Manag. 2014;10(3):159.
24. Soeffing JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abus Treat. 2009;37(4):426–30.
25. Alford DP, LaBelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011;171(5):425–31.
26. Fiellin DA, Moore BA, Sullivan LE, et al. Long-term treatment with buprenorphine/naloxone in primary care: results at 2–5 years. Am J Addict. 2008;17(2):116–20.